US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Correction: Double Bond Pharmaceutical to Present Clinical Real-World Evidence Data for SI053 at the 2026 Society for Neuro-Oncology (SNO) Annual Meeting in Philadelphia

The correction concerns an incorrectly included MAR labelUPPSALA, SWEDEN — July 21, 2026 — Double Bond Pharmaceutical AB (publ) (“DBP” or the “Company”) today announced that its abstract highlighting clinical Real-World Evidence (RWE) data for its lead neuro-oncology candidate, SI053 (Temodex), has been accepted for presentation at the 31st Annual Meeting of the Society for Neuro-Oncology (SNO). The SNO Annual Meeting, widely recognized as the premier global event in neuro-oncology, will take place November 12–15, 2026, at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.

Double Bond Pharmaceutical to Present Clinical Real-World Evidence Data for SI053 at the 2026 Society for Neuro-Oncology (SNO) Annual Meeting in Philadelphia

UPPSALA, SWEDEN — July 21, 2026 — Double Bond Pharmaceutical AB (publ) (“DBP” or the “Company”) today announced that its abstract highlighting clinical Real-World Evidence (RWE) data for its lead neuro-oncology candidate, SI053 (Temodex), has been accepted for presentation at the 31st Annual Meeting of the Society for Neuro-Oncology (SNO). The SNO Annual Meeting, widely recognized as the premier global event in neuro-oncology, will take place November 12–15, 2026, at the Pennsylvania Convention Center in Philadelphia, Pennsylvania. As part of the official conference proceedings, the

Double Bond Pharmaceutical submits abstract with final RWE data for Temodex to the SNO Meeting in Philadelphia

Double Bond Pharmaceutical International AB (publ) (“DBP”) today announces that a scientific abstract based on final clinical data from the company's extensive Real-World Evidence (RWE) study of Temodex has been submitted for review to the scientific committee of the Society for Neuro-Oncology (SNO), ahead of the annual meeting in Philadelphia, USA. The abstract presents the final results of a retrospective cohort study encompassing a total of 375 patients who underwent surgical resection for malignant primary brain tumors. The purpose of the study was to evaluate the clinical efficacy

Double Bond Pharmaceutical’s Abstract on Temodex Accepted for Presentation at EANS2026

Double Bond Pharmaceutical AB (publ) (“DBP”) announces that a scientific abstract regarding its lead product candidate, Temodex, has been accepted for presentation at the upcoming Congress of the European Association of Neurosurgical Societies (EANS) 2026. The presentation will provide a comprehensive dive into the final analysis of the company's Real-World Evidence (RWE) study, offering granular insights into various patient cohorts. As previously disclosed, the final analysis of this RWE study reinforces that Temodex delivers a clinically significant survival benefit in the treatment

Double Bond Pharmaceutical Announces Final Survival Data from Extensive Temodex Study: 5.6-Month Survival Advantage Confirmed

Double Bond Pharmaceutical AB (publ) ("DBP") reports the final data from its extensive retrospective study of Temodex, confirming a statistically significant 5.6-month survival advantage for patients with malignant primary brain tumors. The final results confirm and strengthen the preliminary findings previously reported, demonstrating a substantial survival benefit for patients. Final Survival Data Analysis The completed study included a total of 375 patients, stratified as follows: · Temodex Group: 124 patients who received Temodex in addition to Standard of Care (SoC). ·

Double Bond Pharmaceutical Collaborates with Karolinska Institutet in Stockholm for Advanced RWE Analysis of Temodex

Uppsala, Sweden – March 26, 2026 – Double Bond Pharmaceutical AB (publ) (“DBP”) announces its participation in the Karolinska Institutet (KI) Career Service Internship Program. Through this initiative, DBP will host a PhD student or Postdoctoral researcher from KI to collaborate on the advanced analysis of Real-World Evidence (RWE) for Temodex, the company’s innovative treatment for glioblastoma.   Strengthening Data Precision for Temodex The KI program is designed to bridge the gap between high-level academic research and industrial application. For DBP, this collaboration

Double Bond Pharmaceutical Reports Preliminary Survival Data from Large-Scale Retrospective Study of Temodex

UPPSALA, SWEDEN – February 19, 2026 – Double Bond Pharmaceutical AB (publ) (“DBP”) today presents preliminary results from an extensive retrospective evaluation of 484 patients treated for malignant primary brain tumors. The analysis is based on data from patients who underwent surgery between 2020 and 2025. The results indicate that the addition of the local chemotherapy Temodex to the surgical workflow provides a statistically significant survival advantage.The results have been submitted for presentation at EANS2026 (European Association of Neurosurgical Societies). Analysis of

Double Bond Pharmaceutical AB Signs Strategic Agreement for Landmark Clinical Study of Temodex® Based on Latest WHO Standards

UPPSALA, SWEDEN (February 12, 2026) – Double Bond Pharmaceutical AB (DBP) has signed a strategic research agreement with the N.N. Alexandrov National Cancer Centre in Belarus. This partnership initiates a study titled: "Study of the efficacy, safety, and therapeutic value of the drug Temodex in real-world clinical practice for the period 2021–2025."A Scientific Milestone: Modern WHO Diagnostics This study represents a significant step forward for brain cancer research. It is a comprehensive mapping of how the treatment performs in practice (Real-World Evidence) for glioblastoma,

Double Bond Pharmaceutical Re-engages Global CRO Allucent to Accelerate Phase 1 Clinical Trial for Glioblastoma Candidate SI-053

Double Bond Pharmaceutical International AB (publ) ("DBP"), a clinical-stage biopharmaceutical company focused on oncology with a strong emphasis on innovative drug delivery for hard-to-treat cancers, including brain tumors, today announced a renewed contract with global clinical service provider Allucent. This extended agreement will further support the robust execution of DBP's upcoming Phase 1 clinical trial for SI-053, an investigational therapy targeting glioblastoma. The renewed contract strengthens the ongoing collaboration on critical clinical trial activities, including

Double Bond Pharmaceutical International AB (publ) Qualifies New Swedish EU-GMP-Approved Supplier for Key Component of SI-053

Double Bond Pharmaceutical International AB (publ) ("DBP"), a clinical-stage biopharmaceutical company, today announced that it has successfully qualified a well-established, EU-GMP-approved pharmaceutical company based in Sweden as an additional potential supplier for dextran phosphate, a key component of SI-053. This internationally recognized partner has now been added to DBP's internal approved supplier list following a thorough qualification process. DBP chooses not to disclose the supplier's name to protect sensitive business information. "This strategic addition significantly

DBP International AB and Vivo Biopharma LLC Extend Asset Purchase and Collaboration Agreements for SI-053

Double Bond Pharmaceutical International AB (publ) ("DBP") and Vivo Biopharma LLC ("Vivo") today announced an extension of their Asset Purchase and Collaboration Agreements for DBP's lead candidate, SI-053, and related assets. The companies are targeting the completion of the transition process by May 1, 2025, with a potential extension of up to 60 days to fulfil the first milestone payment. The original agreements, signed on September 17, 2023, cover SI-053, a locally acting formulation of temozolomide designed for the treatment of glioblastoma. The drug candidate received Orphan Drug

DBP International AB Optimizes Manufacturing Process for SI-053 Ahead of Phase 1 Clinical Trial in Glioblastoma

Double Bond Pharmaceutical International AB (publ) ("DBP" or "The Company", org. No. 556991-6082) has taken a significant step toward initiating the Phase 1 clinical trial of its lead product, SI-053, for glioblastoma patients. DBP has successfully completed improvements to the manufacturing process of SI-053, ensuring readiness for the upcoming trial.A key enhancement focuses on securing the quality of dextran phosphate, a critical excipient that forms SI-053’s hydrogel with unique physical and chemical properties. The entire supply chain and manufacturing process comply with EU-cGMP

DBP International AB: transition of the SI053 clinical trials protocol to a new Clinical Trial Information System has been completed

Double Bond Pharmaceutical International AB (publ) ("DBP" or "The Company", org. No. 556991-6082) is pleased to announce the successful transition of its clinical study "An open-label dose escalation study to estimate the maximum tolerated dose (MTD), identify dose-limiting toxicities (DLTs), and study pharmacokinetics following a single dose of intracranially administered temozolomide-based SI-053 as an add-on to the current standard of care (SoC) in adult patients with newly diagnosed glioblastoma (GBM)," to a new Clinical Trial Information System (CTIS). Adoption to this on-line system

DBP International AB and Vivo Biopharma LLC: Revised Asset Purchase and Collaboration Agreements

Double Bond Pharmaceutical International AB (publ) (“DBP”) and Vivo Biopharma LLC (“Vivo”), today announced an amendment to the Asset Purchase and Collaboration Agreements for DBP’s SI-053 and related assets, originally signed on September 17, 2023.  SI-053 is a locally acting formulation of temozolomide for the treatment of glioblastoma, which received Orphan Drug Designation from the European Medicines Agency in 2016. Recently, SI-053 received both Competent Authority and Ethics Committee approvals to initiate a Phase 1 clinical trial in two Western European countries. The amendment to

DBP International AB: European patent for the technology platform BeloGal® is granted

Double Bond Pharmaceutical International AB (publ) ("DBP" or the "Company", org. no. 556991-6082) has today, May 29, 2024, received information about the granting of a European patent application for organ-specific administration of hydrophilic cancer drugs to the liver. This applies, among other things, to one of the company's frontline products SA-033 for the treatment of liver cancer, which is based on the technology platform BeloGal®. The patent approval means protection for the product in 26 countries within the European Patent Office (EPO) at least until the year 2035. "The granted

DBP International AB: Brazilian patent for Temodex / SI-053 is granted

Double Bond Pharmaceutical International AB (publ) ("DBP" or "The Company", org. No. 556991-6082) has today, January 23[rd] 2024, received information of the approval of a Brazilian patent application concerning the company's front-line product Temodex / SI-053.Patent approval provides protection for the technology and the product in Brazil until at least 2036. "This is an important milestone in the development of SI-053 to get product patented and this is very good news for the company especially now prior starting clinical trials”, comments Igor Lokot, CEO of DBP. – “We also have other

DBP International AB: Canadian patent for Temodex / SI-053 is granted

Double Bond Pharmaceutical International AB (publ) ("DBP" or "The Company", org. No. 556991-6082) has today, January 9[th] 2024, received information of the approval of a Canadian patent application concerning the company's front-line product Temodex / SI-053. Patent approval provides protection for the technology and the product in Canada until at least 2036. "This is an important milestone in the development of SI-053 to get product patented and this is very good news for the company especially now prior starting clinical trials”, comments Igor Lokot, CEO of DBP. – “We also have

Supplement to Press Release: DBP International AB and Vivo Biopharma LLC Enter into Asset Purchase and Collaboration agreements to Develop and Commercialize a novel Glioblastoma Treatment

The press release is supplemented with the paragraph "Further details of the agreements"Double Bond Pharmaceutical International AB (publ) (“DBP”) and Vivo Biopharma LLC (“Vivo”), a wholly owned subsidiary of Sauvie Inc. (“Sauvie”) today announced that they have entered into an asset purchase, collaboration and transition agreements for DBP’s SI-053 development product and related assets. SI-053 is a locally acting formulation of temozolomide for the treatment of glioblastoma and it received Orphan Drug Designation from the European Medicines Agency in 2016.  Recently, SI-053 received both

DBP International AB and Vivo Biopharma LLC Enter into Asset Purchase and Collaboration agreements to Develop and Commercialize a novel Glioblastoma Treatment

Double Bond Pharmaceutical International AB (publ) (“DBP”) and Vivo Biopharma LLC (“Vivo”), a wholly owned subsidiary of Sauvie Inc. (“Sauvie”) today announced that they have entered into an asset purchase, collaboration and transition agreements for DBP’s SI-053 development product and related assets. SI-053 is a locally acting formulation of temozolomide for the treatment of glioblastoma and it received Orphan Drug Designation from the European Medicines Agency in 2016.  Recently, SI-053 received both Competent Authority and Ethics Committee approvals to initiate a Phase 1 clinical trial

DBP International AB: Full approval for SI-053 from The Ethics Commission of the Faculty of Medicine of Cologne University in Germany has been received

Double Bond Pharmaceutical International AB (publ) ("DBP") is very delighted to announce that the company has received for its product SI-053 full approval for starting clinical trials in Germany, in patients with glioblastoma.Up to now, the SI-053 has obtained all approvals from the countries (Germany and the Netherlands) where the clinical trial is to be conducted. "We are very excited to reach this crucial milestone. It is a result of lots of hard work done by our excellent colleagues, our preclinical and clinical partners, external consultants and KOLs, and all our investors who have

Correction: DBP International AB: investee company Bio Vitos has yesterday reached agreement with Hemcheck

The correction refers to the letter in the press release on February 8 at 07:48 CEST: The MAR label was put there by mistake and the agreement between Bio Vitos and Hemcheck was signed yesterday.   Double Bond Pharmaceutical International AB (publ) ("DBP") notes the announcement released earlier yesterday by Hemcheck Sweden AB (“Hemcheck”) and is pleased to announce that its 20% owned investee company Bio Vitos has today entered into an agreement with Hemcheck, a company listed on the Nasdaq Stockholm (the “Agreement”).  As part of the Agreement Hemcheck will create a new subsidiary (“

DBP International AB: investee company Bio Vitos has today reached agreement with Hemcheck

Double Bond Pharmaceutical International AB (publ) ("DBP") notes the announcement released earlier yesterday by Hemcheck Sweden AB  (“Hemcheck”) and is pleased to announce that its 20% owned investee company Bio Vitos has today entered into an agreement with Hemcheck, a company listed on the Nasdaq Stockholm (the “Agreement”).  As part of the Agreement Hemcheck will create a new subsidiary (“NewCo”) and transfer all current business and assets of Hemcheck to this new subsidiary. Under the terms of the Agreement, Bio Vitos has agreed to provide the NewCo with  SEK1.23 million in cash, plus

DBP International AB: favorable response for SI-053 from The Ethics Commission of the Faculty of Medicine of Cologne University in Germany has been received

Double Bond Pharmaceutical International AB (publ) ("DBP") is about to take a very important step towards the start of clinical trial phase 1 in Germany of its front-line product SI-053 in patients with glioblastoma – a positive response from The Ethics Commission of the Faculty of Medicine of Cologne University (Central Ethics Committee, CEC) in Germany  has now been received. This favorable approval is conditional in nature, and DBP is currently revising Informed Consent form and supporting forms with minor changes as per the recommendation from the CEC. Germany is accordingly the second

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe